HEALTHCARE / SERVICE 07

Financial Cleanliness and Metrics for Dental Practices

Dental buyers and DSOs pay 5 to 11x adjusted EBITDA when production per provider, collection rate, and hygiene utilization are documented, defensible, and repeatable. We build the financial infrastructure that separates a premium sale from a discounted one.

Request a 15-Minute Call

No cost. 15 minutes. No obligation.

We will respond within one business day.

Dental buyers and DSOs pay 5 to 11x adjusted EBITDA when production per provider, collection rate, and hygiene utilization are documented, defensible, and repeatable. We build the financial infrastructure that separates a premium sale from a discounted one.

The financial cleanliness and metrics problem in dental practices

Most dental practice owners cannot tell you their true production per provider, their collection rate by payer class, or whether hygiene is underutilized relative to clinical capacity. Financial statements arrive from bookkeepers who code everything to general ledger accounts with no link to production, fee schedules, or reimbursement. When a DSO or private buyer runs due diligence, they discount the purchase price for every KPI they cannot verify, every fee schedule realization gap they uncover, and every collection leak they find in your aging. If your financials do not map cleanly to production per operatory, hygiene production independent of the owner, and documented fee schedule realization by payer, you are leaving seven figures on the table or you will not close at all.

Where value leaks

  • Production recorded in your practice management system does not reconcile to revenue on the P&L, creating a diligence red flag that buyers discount heavily.
  • Collection rate sits below 95 percent because adjustments, write-offs, and payer shortfalls are not tracked by fee schedule or insurance class.
  • Hygiene utilization is unmeasured, so buyers assume the practice is underperforming and reduce the multiple or walk away.
  • Owner clinical production is not separated from associate production, making transferability impossible to prove and triggering earnout structures that reduce upfront cash.
  • Fee schedule realization by payer is not documented, so buyers assume margin compression and apply a lower multiple to adjusted EBITDA.
  • Overhead allocation is not calibrated to production per provider, hiding inefficiencies that buyers will find and penalize during due diligence.
  • Compensation is not structured for tax efficiency, inflating reported expenses and deflating adjusted EBITDA before sale.

What we build for dental practices

Monthly production per provider reporting that reconciles practice management system data to revenue on the P&L, segmented by owner, associate, and hygiene.

Collection rate tracking by payer class, with aging analysis, adjustment reporting, and fee schedule realization benchmarks that buyers can verify.

Hygiene utilization dashboard tied to operatory capacity, showing production per hygiene hour and independence from owner clinical activity.

Overhead allocation model that maps expenses to production per provider, isolating owner compensation and non-recurring costs to calculate defensible adjusted EBITDA.

Fee schedule realization analysis by insurance class and payer, documenting margin by production source and identifying optimization opportunities before sale.

Clean, auditable chart of accounts that separates clinical production from administrative overhead, owner distributions from practice expenses, and recurring from non-recurring costs.

Exit-ready financial package with trailing twelve months of production, collection, and adjusted EBITDA reporting that DSOs and private buyers expect in LOI and due diligence.

KPIs this moves for dental practices

  • Production per provider becomes measurable, trended, and defensible, allowing buyers to model post-acquisition performance and pay a premium multiple.
  • Collection rate improves and is documented by payer class, proving that revenue is not at risk from fee schedule compression or aging leakage.
  • Hygiene utilization is quantified and optimized, demonstrating that production is not owner-dependent and that capacity exists for growth.
  • Fee schedule realization is tracked by insurance type, giving buyers confidence that margins are stable and that payer mix is not eroding profitability.
  • Overhead as percent of revenue is calibrated to production per provider, isolating inefficiencies and maximizing adjusted EBITDA before sale or transition.
  • Buyer and exit lens for dental practices

    DSOs and private equity buyers pay 5 to 11x adjusted EBITDA for dental practices, with solo and add-on acquisitions at 5 to 8x, regional platforms at 9 to 11x, and consolidated groups above $5M in EBITDA at 10 to 12x or higher. They reach the top of that range when production per provider is documented and repeatable, hygiene production is independent of the owner, collection rate is above 95 percent and verified by payer class, and fee schedule realization is tracked and optimized. If your financials cannot prove those KPIs, buyers either discount the multiple, structure earnouts that defer cash, or walk away during diligence.

    FAQ

    Financial Cleanliness and Metrics questions for dental practices

    Why does production per provider matter more than total revenue in a dental sale?

    Buyers model post-acquisition cash flow based on production per operatory and per provider, not total revenue. If your practice management system shows $1.2M in production but your P&L shows $950K in revenue and you cannot reconcile the difference, the buyer assumes collection problems, fee schedule erosion, or accounting errors. They will discount the purchase price or require you to true up the gap before closing. We reconcile production to revenue monthly so that your KPIs are defensible in diligence.

    How do DSOs verify collection rate during diligence, and what happens if it is below benchmark?

    DSOs pull your practice management aging report, compare it to your financial statements, and calculate collection rate by payer class. If your rate is below 95 percent, they assume you have fee schedule realization problems, poor billing processes, or insurance mix that compresses margin. They reduce the EBITDA multiple or require post-close earnouts tied to hitting collection benchmarks. We build monthly collection rate tracking by payer so you can optimize before you go to market.

    What does it mean to separate owner clinical production from associate production, and why does it affect my multiple?

    If 70 percent of your production is owner clinical work and you cannot prove that associates or hygiene can sustain revenue post-sale, buyers view the practice as non-transferable. They either structure earnouts that require you to stay for two to three years, reduce the upfront cash, or apply a lower multiple to adjusted EBITDA. We build production reporting that isolates owner, associate, and hygiene activity so you can demonstrate transferability and command a higher multiple.

    How does fee schedule realization tracking improve my adjusted EBITDA before sale?

    Fee schedule realization measures how much you actually collect per procedure relative to your fee schedule, segmented by PPO, managed care, and fee-for-service. If you are writing off 30 percent to insurance contracts but do not track which payers or procedures are driving the loss, you cannot optimize before sale. We document realization by payer class, identify margin leaks, and help you adjust payer mix or fee schedules to maximize adjusted EBITDA and prove margin stability to buyers.

    More for Dental Practices

    More healthcare verticals

    Start with where you actually stand.

    The Keystone Value Creation Assessment audits your last 12 to 36 months and gives you a written summary whether you engage us or not. If there is not a clear opportunity to create value, we will tell you directly.

    CallBook a CallEmail